StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a report issued on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
The stock has a market capitalization of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.61. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.35 and a current ratio of 1.35. Genocea Biosciences has a one year low of $0.00 and a one year high of $0.00.
About Genocea Biosciences
Further Reading
- Five stocks we like better than Genocea Biosciences
- What is a Secondary Public Offering? What Investors Need to Know
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- Stock Average Calculator
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- What is the S&P/TSX Index?
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
